Ensign Peak Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Ensign Peak Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.1M	Buy	204,336 +69,920	+52%	+$4.05M	0.03%	323
2025 Q4	$5.54M	Hold	134,416	–	–	0.01%	503
2025 Q3	$5.29M	Hold	134,416	–	–	0.01%	580
2025 Q2	$2.5M	Buy	+134,416	New	+$2.52M	﹤0.01%	829
2021 Q2	–	Sell	-198	Closed	-$37K	–	1838
2021 Q1	$37K	Buy	+198	New	+$33.3K	﹤0.01%	1814
2020 Q3	–	Sell	-792	Closed	-$95K	–	1749
2020 Q2	$95K	Sell	792 -4,127	-84%	-$581K	﹤0.01%	1632
2020 Q1	$495K	Sell	4,919 -1,592	-24%	-$295K	﹤0.01%	1400
2019 Q4	$1.58M	Buy	+6,511	New	+$1.22M	﹤0.01%	1161

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's DNTH Position: Q1 2026 in Review

Ensign Peak Advisors increased its Dianthus Therapeutics (DNTH) stake by 52% in Q1 2026, buying an estimated $4.05M and bringing the position to 204,336 shares worth $17.1M. The position accounts for 0.03% of the portfolio, ranked #323.

Ensign Peak Advisors first reported a position in DNTH in Q4 2019 and has held it in 8 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Ensign Peak Advisors held 204,336 shares of Dianthus Therapeutics worth $17.1M as of Q1 2026.
Ensign Peak Advisors bought 69,920 Dianthus Therapeutics shares in Q1 2026, an estimated $4.05M.
Dianthus Therapeutics made up 0.03% of Ensign Peak Advisors's portfolio in Q1 2026, its #323 holding.
Ensign Peak Advisors first reported a position in Dianthus Therapeutics in Q4 2019 and has held it in 8 quarters since.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.